Presatovir

Drug Profile

Presatovir

Alternative Names: GS-5806

Latest Information Update: 12 Jun 2017

Price : $50

At a glance

  • Originator Gilead Sciences
  • Class Amines; Antivirals; Chlorophenols; Piperidines; Pyrazoles; Pyrimidines; Pyrrolidines; Small molecules; Sulfonamides
  • Mechanism of Action Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Respiratory syncytial virus infections

Most Recent Events

  • 09 May 2017 Gilead complete a phase IIb trial for Respiratory syncytial virus infections (In adults, In the elderly) in USA, France, South Korea, Sweden, Switzerland, Germany and the Netherlands (NCT02254421)
  • 12 Apr 2017 Gilead Sciences completes a phase IIb trial for Respiratory syncytial virus infections in USA, Australia, Belgium, France, Israel, Italy, South Korea, New Zealand , the Netherlands, Poland and the United Kingdom (NCT02135614)
  • 01 Sep 2015 Gilead Sciences plans a phase II trial for Respiratory syncytial virus infections (In adults, In the elderly) in USA, Austria, Australia, Belgium, Canada, France, Germany and United Kingdom (NCT02534350)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top